Reuters

Vivalis, GSK win OK for flu vaccine test on humans

PARIS, Nov 24 (Reuters) - French biotech firm Vivalis and British partner GlaxoSmithKline have won U.S. clearance to begin testing on humans for the first time flu vaccines which were produced using ...
PharmTech

Vivalis and Intercell to Create New Biotechnology Company

Vivalis and Intercell have agreed to the terms of a merger to create a new European biotechnology company called Valneva that will specialize in vaccines and antibodies. Vivalis and Intercell have ...
Reuters

Vivalis to buy Intercell in European biotech merger

LONDON/PARIS (Reuters) - France's Vivalis and Austrian vaccine specialist Intercell are linking up in a rare cross-border deal that shows the need for Europe's fledgling biotech companies to grow in ...
Yahoo

Successful Growth of BioDiem's Virus in VIVALIS EB66(R) Cell Line

* BioDiem confirms successful and abundant growth of its virus in VIVALIS' proprietary EB66(®) cell line in Stage 1 of its collaboration with VIVALIS. * The next stage of the project will use known ...
Investing

Vivalis To Merge With Intercell

Vivalis shareholders will own 55% of Valneva, with Intercell’s shares being converted at a 39% premium to the pre-deal share prices. An extra 8.6m shares will be issued to former Intercell ...
GEN

Sanofi Pasteur Pays Vivalis €3M for Access to Human mAb Platform for Infectious Diseases

Companies will collaborate on antibody discovery against multiple targets. Vaccines company Sanofi Pasteur is paying Vivalis €3 million up front for exclusive access to the latter’s Humalex® platform ...
GEN

Novavax to Use Vivalis’ Duck Embryonic Stem Cell Line for Vaccine Production

Firm is developing VLP-based vaccines. Vivalis has granted Novavax the right to use its EB66® cell line for the production of VLP-based vaccines against several new potential viruses. The EB66 cell ...
PharmaTimes

Vivalis and Intercell unveil merger plan

France's Vivalis is buying Austrian vaccines specialist Intercell in a deal the firms say will result in the "creation of a European biotech leader". France’s Vivalis is buying Austrian vaccines ...
FierceBiotech

VIVALIS PARTNERS WITH SANOFI PASTEUR FOR THE DISCOVERY OF HUMAN MONOCLONAL ANTIBODIES AGAINST INFECTIOUS DISEASES

NANTES, FRANCE--(Marketwire - June 8, 2010) - VIVALIS (NYSE Euronext: VLS) announced today the signature with Sanofi Pasteur, the vaccines division of sanofi-aventis Group (Euronext: SAN and NYSE: SNY ...
FierceBiotech

GeoVax Partners with Vivalis for Use of Its Revolutionary EBx(R) Technology to Manufacture Its MVA HIV/AIDS Vaccine

"Vivalis is pleased to enter in this collaboration with GeoVax, one of the most advanced companies worldwide in the field of HIV vaccine development. This agreement aims at developing a Vivalis ...
technologynetworks

Vivalis and Intercell Merge to form Valneva

Valneva SE announces the completion of the merger of equals between Vivalis and Intercell, creating a new European biotech company focusing on vaccines and antibodies, striving to become a leader in ...